ReviewFrontiers in allergy2025
Enhancing allergy diagnosis: mass spectrometry as a complementary technique to the basophil activation test.
Review in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A narrative review of house dust mite allergy: species distribution and allergen sensitisation patterns across tropical regions.Frontiers in allergy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate diagnostic tools for allergic conditions are essential for effective treatment. Traditional methods, such as skin prick tests (SPT) and specific IgE measurements are widely used, but they have limitations in sensitivity and specificity for certain allergens. While the Basophil Activation Test (BAT) offers improved specificity, particularly for allergens such as peanuts and sesame, its practicality and accessibility remain challenges. Mass spectrometry (MS) has recently gained recognition as a promising complementary tool in allergy diagnostics, offering high analytical precision and the capability to detect a wide range of allergen-specific biomarkers. This review explores the integration of MS into allergy diagnostics, emphasizing its potential to enhance BAT applications, particularly for non-responders. We discuss the underlying mechanisms, recent research highlighting its efficacy, and the technical challenges that must be addressed for clinical adoption. Additionally, we examine the standardization requirements and ethical considerations necessary for MS to become a routine diagnostic tool. Finally, we consider the future of allergy diagnostics, highlighting how MS technology could contribute to more precise, personalized, and patient-centered care in allergy management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.